The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β
Abstract
Postmenopausal osteoporosis, the most common bone disease in the developed world, is associated with estrogen deficiency. This deficiency induces increased generation and activity of osteoclasts, which perforate bone trabeculae, thus reducing their strength and increasing fracture risk. Estrogen replacement prevents these effects, indicating that estrogen negatively regulates osteoclast formation and function, but how it does this is unclear. Because functional osteoclast life span and thus the amount of bone that osteoclasts resorb could also be enhanced following estrogen deficiency, and since sex steroids regulate apoptosis in other target tissues, we investigated whether estrogen may affect osteoclast function by promoting apoptosis. 17 beta-Estradiol promoted apoptosis of murine osteoclasts in vitro and in vivo by two- to threefold. Tamoxifen, which has estrogenic effects on bone resorption, and transforming growth factor-beta 1 (TGF-beta), whose production by osteoblasts is increased by estrogen, had similar effects in vitro. Anti-TGF-beta antibody inhibited TGF-beta-, estrogen- and tamoxifen-induced osteoclast apoptosis, indicating that TGF-beta might mediate this effect. These findings suggest that estrogen may prevent excessive bone loss before and after the menopause by limiting osteoclast life span through promotion of apoptosis. The development of analogues to promote this mechanism specifically could be a useful and novel therapeutic approach to prevent postmenopausal osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The estrogen suppresses the osteoclast formation and activity as well as induces osteoclast apoptosis [16, 76, 104, 154].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [154]
In the citing paper
“The estrogen suppresses the osteoclast formation and activity as well as induces osteoclast apoptosis [16, 76, 104, 154].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [154]
In the citing paper
“In addition, estrogen can also increase TGF-β and osteoprotegerin (OPG) levels, which inhibit osteoclast differentiation [[58], [59], [60]].”
From Emerging role of liver-bone axis in osteoporosis (2024) · cites this paper as [60]
Citations
Cites
PARFITT, A. M., Mathews, C. H. E., Villanueva, A. R., Kleerekoper, M., Frame, B., & Rao, D. S. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111096 · Cited by 1,542
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440
Self-citationBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D., Mundy, G. R., & Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,039
Self-citationBone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function
Minkin, C. (1982) · Calcified Tissue International · doi:10.1007/bf02411252 · Cited by 992
Continuous c-fos expression precedes programmed cell death in vivo
Smeyne, R. J., Vendrell, M., Hayward, M. D., Baker, S. J., Miao, G. G., Schilling, K., Robertson, L. M., Curran, T., & Morgan, J. I. (1993) · Nature · doi:10.1038/363166a0 · Cited by 775
Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., BOYDE, A., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-122-4-1373 · Cited by 731
Self-citationPerspectives: How many women have osteoporosis now?
Melton, J. L. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100202 · Cited by 596
Cytokines and Estrogen in Bone: Anti-Osteoporotic Effects
Horowitz, M. C. (1993) · Science · doi:10.1126/science.8480174 · Cited by 451
Tashjian, A. H., Voelkel, E. F., Lazzaro, M., Singer, F. R., Roberts, A. B., Derynck, R., Winkler, M. E., & Levine, L. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.13.4535 · Cited by 381
Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype.
Erlebacher, A., & Derynck, R. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.132.1.195 · Cited by 372
Flagged first, then by citations
Cited by
Sorted by citations
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,639
“an effect seemingly mediated by TGFb (139).”
BackgroundOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
“Some systemic and local factors that regulate development and interplay between osteoclasts and osteoblasts have been identified (Mundy 1993a,b; Erlebacher and Derynck 1996; Manolagas and Jilka 1995; Hughes et al. 1996; Pacifici 1996).”
BackgroundBiology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells
Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J., & Cerri, P. S. (2015) · BioMed Research International · doi:10.1155/2015/421746 · Cited by 2,044
“These cells exhibit a thin and flat nuclear profile; its cytoplasm extends along the bone surface and displays few cytoplasmic organelles such as profiles of rough endoplasmic reticulum and Golgi apparatus [50] (Figure 2(b)).”
BackgroundPathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Sex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
“Second, it induces a remodeling imbalance by prolonging the resorption phase [osteoclast apoptosis is reduced (33)] and shortening the formation phase [osteoblast apoptosis is increased (32)].”
BackgroundMinireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
“However, not all regulation of the osteoclast is exclusively via the osteoblast because calcitonin acts directly on osteoclastic cells (40), and estrogen has been shown to induce apoptosis of osteoclasts (41) as well as inhibit osteoclast differentiation by interfering with RANK signaling, principally RANKL-induced JN…”
Feng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272
“TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation.”
BackgroundInfluentialLegumes and soybeans: overview of their nutritional profiles and health effects
Messina, M. J. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/70.3.439s · Cited by 1,224
“This last finding may be particularly important given the role that TGFb may have in inhibiting the growth of cancer cells (138–140).”
BackgroundInfluentialSambrook, P. N., & Cooper, C. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,201
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,185
“(74–79)Estrogen deficiency also increases activation(80) and decreases apoptosis (81) of mature osteoclasts, and these effects are also reversed by estrogen.”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O’Brien, C. A., Bodenner, D., Li, H., Han, K., Gregorio, G. B. D., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,163
Self-citationRequirement for NF-κB in osteoclast and B-cell development
Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., & Siebenlist, U. (1997) · Genes & Development · doi:10.1101/gad.11.24.3482 · Cited by 996
Self-citationEstrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990
Changes in Proinflammatory Cytokine Activity after Menopause
Pfeilschifter, J., Köditz, R., Pfohl, M., & Schatz, H. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0456 · Cited by 929
Pathogenesis of bone fragility in women and men
Seeman, E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08706-8 · Cited by 909
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890
“Opposite effects on osteoclast and osteoblast apoptosis have also been demonstrated for TGF-β (31, 62).”
BackgroundEstrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
“A direct effect of estrogens on osteoclasts in vivo is supported by the finding that E2 promotes apoptosis of murine osteoclasts (200).”
Transforming Growth Factor-β1 to the Bone
Janssens, K., ten Dijke, P., Janssens, S., & Van Hul, W. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0001 · Cited by 710
“, promotion of murine osteoclast apoptosis (261).”
BackgroundEstrogen deficiency induces bone loss by enhancing T-cell production of TNF-α
Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705
“Discussion Estrogen prevents bone loss through multiple effects on bone marrow and bone cells, which result in decreased osteoclast formation (4, 5), increased osteoclast apoptosis (25), and decreased capacity of mature osteoclasts to resorb bone (26).”
BackgroundRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
“In addition, estrogen upregulates TGF-β (8), an inhibitor of bone resorption that decreases the activity and increases the rate of apoptosis of mature osteoclasts (9).”
BackgroundYeh, S., Tsai, M.-Y., Xu, Q., Mu, X., Lardy, H. A., Huang, K., Lin, H., Yeh, S.-D., Altuwaijri, S., Zhou, X., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212474399 · Cited by 683
Self-citationOsteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and Cytokines
Jilka, R. L., Weinstein, R. S., Bellido, T., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.5.793 · Cited by 578
“and in the case of transforming growth factor-b (TGF-b) osteoclast apoptosis,((8)) we reasoned further that growth factors and cytokines that influence osteoblast replication and differentiation, such as interleukin-6 (IL-6)–type cytokines and TGF-b, may also influence osteoblast apoptosis.”
BackgroundInfluentialThe role of estrogen and androgen receptors in bone health and disease
Manolagas, S. C., O’Brien, C. A., & Almeida, M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.179 · Cited by 598
Cell biology of the osteoclast
Roodman, G. D. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00061-2 · Cited by 583
“Hughes and coworkers [118] recently developed an in vitro system for examining apoptosis in osteoclasts.”
BackgroundAging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 602
“Usually, estrogen may inhibit osteoclast formation and activity by increasing the production of osteoprotegerin (OPG), or transforming growth factor b (TGF-b) [Hofbauer et al. 1999; Hughes et al. 1996].”
BackgroundManolagas, S. C. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.385 · Cited by 532
“This phenomenon is most likely due to the removal of pro-apoptotic effects of estrogens on osteoclasts (Hughes et al., 1996).”
BackgroundLi, Y., Toraldo, G., Li, A., Yang, X., Zhang, H., Qian, W.-P., & Weitzmann, M. N. (2007) · Blood · doi:10.1182/blood-2006-07-037994 · Cited by 520
Estrogen Inhibits Bone Resorption by Directly Inducing Apoptosis of the Bone-resorbing Osteoclasts
Kameda, T., Mano, H., Yuasa, T., Mori, Y., Miyazawa, K., Shiokawa, M., Nakamaru, Y., 広井, 恵., Hiura, K., Kameda, A., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.4.489 · Cited by 519
“Moreover, Hughes et al. ( 21 ) recently reported that estrogen promoted apoptosis of murine osteoclast‐like cells mediated by TGF- b in a mixed cell population in culture.”
BackgroundCompston, J. E. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.419 · Cited by 522
Shevde, N. K., Bendixen, A. C., Dienger, K. M., & Pike, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130200197 · Cited by 502
Mechanical Strain and Bone Cell Function: A Review
Ehrlich, P. J., & Lanyon, L. E. (2002) · Osteoporosis International · doi:10.1007/s001980200095 · Cited by 509
“Estrogen also promotes osteoclast apoptosis [205,206], reducing their capacity for resorption.”
BackgroundOsteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption
McDonald, M. M., Khoo, W. H., Ng, P. Y., Xiao, Y., Zamerli, J., Thatcher, P., Kyaw, W., Pathmanandavel, K., Grootveld, A. K., Moran, I., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.002 · Cited by 433
“, 1995), estrogen (Hughes et al., 1996), and mechanical force (Kobayashi et al.”
Flouriot, G., Brand, H., Denger, S., Métivier, R., Koš, M., Reid, G., Sonntag‐Buck, V., & Gannon, F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4688 · Cited by 419
Pathophysiology of Osteoporosis
Armas, L. A. G., & Recker, R. R. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.006 · Cited by 466
The Death of Osteocytes via Apoptosis Accompanies Estrogen Withdrawal in Human Bone
Tomkinson, A., REEVE, J., Shaw, R. W., & Noble, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4200 · Cited by 417
“In part, this may be caused by increased osteoclast survival, because estrogen promotes osteoclast apoptosis ( 15 ).”
BackgroundYamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., Takeshita, S., Wagner, E. F., Noda, M., Matsuo, K., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610701200 · Cited by 414
Self-citationRegulation of Osteoclast Function
Suda, T., Nakamura, I., Jimi, E., & Takahashi, N. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.869 · Cited by 404
New Developments in the Pathogenesis and Treatment of Steroid-Induced Osteoporosis
Manolagas, S. C., & Weinstein, R. S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.7.1061 · Cited by 382
“Strong support for this concept has been provided by the elucidation of the pathogenesis of postmenopausal and senile osteoporosis and, specifically, the realization that the bone loss underlying either form of the disease is due to changes in the birth((13,14)) as well as death rate of bone cells.((10)) As it will be…”
BackgroundThe Osteoclast: Friend or Foe?
Novack, D. V., & Teitelbaum, S. L. (2007) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.151431 · Cited by 402
Mechanisms of sex steroid effects on bone
Syed, F., & Khosla, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.097 · Cited by 380
Riggs, B. L., & PARFITT, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 379
“Preliminary studies with PTH(1-84) show comparable increases in LS-BMD, although the changes in FN-BMD were not significant.”
BackgroundInfluentialPathophysiology of Age-Related Bone Loss and Osteoporosis
Khosla, S., & Riggs, B. L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.07.009 · Cited by 376
“TGF-b, in turn, has been shown to induce apoptosis of osteoclasts [30].”
BackgroundReciprocal Role of ERK and Nf-κb Pathways in Survival and Activation of Osteoclasts
Miyazaki, T., Katagiri, H., Kanegae, Y., Takayanagi, H., Sawada, Y., Yamamoto, A., Pando, M. P., Asano, T., Verma, I. M., Oda, H., et al. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.2.333 · Cited by 376
“Recent findings suggest that the survival of osteoclasts is precisely regulated through interactions with supporting cells as well as by the action of several cytokines (Fuller et al., 1993; Jimi et al., 1995; Hughes et al., 1996; Selander et al., 1996; Kameda et al., 1997).”
BackgroundTranscriptional Regulatory Cascades in Runx2-Dependent Bone Development
Liu, T. M., & Lee, E. H. (2012) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2012.0527 · Cited by 377
“Estrogen deficiency causes bone loss and osteoporosis by increasing the generation and activity of osteoclasts.(3) Excessive glucocorticoid also results in osteoporosis, which is a major cause for bone fractures in the elderly, by decreasing bone formation(4) and promoting bone resorption.”
BackgroundYano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363
“kines that regulate osteoclastic bone resorption, including tumor necrosis factor (TNF),((12)) interleukin-1,((12)) interleukin-6,((13)) and transforming growth factor-b,((14)) are thought”
BackgroundThe role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 366
“TGF-b is certainly an important central regulator that influences ovariectomyinduced bone loss (100), T-cell tolerance and autoimmunity (112), and bone cell survival (16, 93).”
BackgroundSrivastava, S. K., Toraldo, G., Weitzmann, M. N., Cenci, S., Ross, F. P., & Pacifici, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010764200 · Cited by 363
Bone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 354
“It has in fact been shown that estrogen receptors in differentiated osteoclasts are functional and cause decreased bone-resorbing activity (Oursler et al., 1991a; Taranta et al., 2002) and enhanced apoptosis (Hughes et al., 1996; Chen et al., 2005).”
Kaneko, H., Arakawa, T., Mano, H., Kaneda, T., Ogasawara, A., Nakagawa, M., Toyama, Y., Yabe, Y., Kumegawa, M., & Hakeda, Y. (2000) · Bone · doi:10.1016/s8756-3282(00)00358-6 · Cited by 347
Weinstein, R. S., Chen, J., Powers, C. C., Stewart, S. A., Landes, R. D., Bellido, T., Jilka, R. L., PARFITT, A. M., & Manolagas, S. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14538 · Cited by 397
Jimi, E., Nakamura, I., Duong, L. T., Ikebe, T., Takahashi, N., Rodan, G. A., & Suda, T. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4320 · Cited by 329
Yamada, Y., Miyauchi, A., Goto, J., Takagi, Y., Okuizumi, H., Kanematsu, M., Hase, M., Takai, H., Harada, A., & Ikeda, K. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.10.1569 · Cited by 318
“The production of TGF-b1 by human osteoblastic cells is stimulated by 17b-estradiol,((31)) and the TGF-b1 contributes to the estrogen-induced apoptosis of osteoclasts, which results in reduced bone resorption.((32)) Thus, TGF-b may mediate the local beneficial effects of systemic hormones, such as estrogen, on bone re…”
BackgroundAbe, E., Yamamoto, M., Taguchi, Y., Lecka‐Czernik, B., O’Brien, C. A., Economides, A. N., Stahl, N., Jilka, R. L., & Manolagas, S. C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.663 · Cited by 319
Kim, H., Peterson, T. G., & Barnes, S. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1418s · Cited by 308
MECHANISMS OF ACTION OF BISPHOSPHONATES
Rodan, G. A. (1998) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.375 · Cited by 301
The Role of Estrogen in the Control of Rat Osteocyte Apoptosis
Tomkinson, A., Gevers, E. F., Wit, J. M., REEVE, J., & Noble, B. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.8.1243 · Cited by 302
“For example, it stimulates apoptosis in osteoclasts((30)) and inhibits apoptosis in nerve cells,((31,32)) endothelial cells,((33)) and some epithelial cells.”
BackgroundGori, F., Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Khosla, S., & Riggs, B. L. (2000) · Endocrinology · doi:10.1210/endo.141.12.7840 · Cited by 309
The Pathophysiology and Treatment of Osteoporosis
Drake, M. T., Clarke, B. L., & Lewiecki, E. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.006 · Cited by 292
Martin-Millan, M., Almeida, M., Ambrogini, E., Han, L., Zhao, H., Weinstein, R. S., Jilka, R. L., O'Brien, C. A., & Manolagas, S. C. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0354 · Cited by 282
Inorganic phosphate induces apoptosis of osteoblast-like cells in culture
Meleti, Z., Shapiro, I. M., & Adams, C. S. (2000) · Bone · doi:10.1016/s8756-3282(00)00346-x · Cited by 266
Weitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 264
“…of the RANK/ RANKL/OPG axis in physiological and pathological bone turnover, a number of cytokines have now been identified that directly promote osteoclastogenesis in a RANKLindependent manner and may contribute to bone loss associated with certain pathological conditions, including inflammation.”
BackgroundAge-Related Bone Loss: Old Bone, New Facts
Chan, G. K., & Duque, G. (2002) · Gerontology · doi:10.1159/000048929 · Cited by 259
Cytokines, bone remodeling, and estrogen deficiency: a 1998 update
Jilka, R. L. (1998) · Bone · doi:10.1016/s8756-3282(98)00077-5 · Cited by 255
Clarke, B. L., & Khosla, S. (2010) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2010.02.014 · Cited by 221
“TGF-β induces apoptosis of osteoclasts [37].”
Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251
The Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton
Spelsberg, T. C., Subramaniam, M., Riggs, B. L., & Khosla, S. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0299 · Cited by 250
“The E induction of apoptosis may be further enhanced in vivo since TGF-b, whose production by OB is enhanced by E, was also shown to induce OCL apoptosis in these cultures (34).”
BackgroundWeinstein, R. S., & Manolagas, S. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00420-9 · Cited by 250
Lewis, J. S., Meeke, K., Osipo, C., Ross, E. A., Kidawi, N., Li, T., Bell, E. L., Chandel, N. S., & Jordan, V. C. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji400 · Cited by 245
Exercise and bone health across the lifespan
Santos, L., Elliott-Sale, K. J., & Sale, C. (2017) · Biogerontology · doi:10.1007/s10522-017-9732-6 · Cited by 274
“1999) or transforming growth factor b (Hofbauer et al. 1999; Hughes et al. 1996), and may also induce apoptosis of osteoclast progenitor cells via blocking of the cytokine receptor activator of NFjB ligand (RANKL) (Lundberg et al.”
BackgroundEstrogen Prevents Glucocorticoid-Induced Apoptosis in Osteoblasts in Vivo and in Vitro1
Gohel, A., McCarthy, M.-B., & Gronowicz, G. (1999) · Endocrinology · doi:10.1210/endo.140.11.7135 · Cited by 244
The Role of the Immune Microenvironment in Bone Regeneration
Yang, N., & Liu, Y. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.61080 · Cited by 252
“In an in vitro osteoclast culture system, TGF-β secreted by B cells induces osteoclast apoptosis; TGF-β further promotes B cells to produce OPG, suggesting that B cells inhibit osteoclast differentiation [74].”
BackgroundImmunoporosis: Role of Innate Immune Cells in Osteoporosis
Saxena, Y., Routh, S., & Mukhopadhaya, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687037 · Cited by 233
Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System
Ponzetti, M., & Rucci, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00236 · Cited by 232
Estrogens and environmental estrogens
Tapiero, H., Ba, G. N., & Tew, K. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00155-x · Cited by 222
Invited Review: Pathogenesis of osteoporosis
Seeman, E. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00564.2003 · Cited by 232
“The life span of osteoblasts, however, decreases, also resulting in less bone formed (31, 40).”
BackgroundSeeman, E. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1340-9 · Cited by 220
“The BMU balance is more negative because estrogen deficiency increases the lifespan of osteoclasts so more bone is resorbed in the BMU, while the lifespan of osteoblasts decreases so less bone is formed as well [23, 24].”
BackgroundWattel, A., Kamel, S., Mentaverri, R., Lorget, F., Prouillet, C., Petit, J.-P., Fardelonne, P., & Brazier, M. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01445-4 · Cited by 220
Mechanism of action of bisphosphonates
Reszka, A. A., & Rodan, G. A. (2003) · Current Osteoporosis Reports · doi:10.1007/s11914-003-0008-5 · Cited by 216
Zhao, W., Byrne, M. H., Boyce, B. F., & Krane, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5481 · Cited by 212
Self-citationFilvaroff, E. H., Erlebacher, A., Ye, J., Gitelman, S. E., Lotz, J. C., Heilman, M., & Derynck, R. (1999) · Development · doi:10.1242/dev.126.19.4267 · Cited by 212
Perspective: Quantifying Osteoblast and Osteocyte Apoptosis: Challenges and Rewards
Jilka, R. L., Weinstein, R. S., PARFITT, A. M., & Manolagas, S. C. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070518 · Cited by 211
Osteoporosis – a current view of pharmacological prevention and treatment
Crockett, J. C., & Das (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s31504 · Cited by 208
“Decades of research indicates that estrogen plays a dominant multifactorial role in maintaining cortical bone formation by supporting osteoblasts and preventing bone resorption by suppressing osteoclast formation and stimulating osteoclast apoptosis.(8,9) Sclerostin”
BackgroundSolakidi, S., Psarra, A. G., Nikolaropoulos, S., & Sekeris, C. E. (2005) · Human Reproduction · doi:10.1093/humrep/dei267 · Cited by 205
“The central role of mitochondria in energy production and cell apoptosis and the known effects of steroid and thyroid hormones on these processes (Hughes et al., 1996; Scheller et al., 2003) led to the hypothesis (Sekeris, 1990) that the hormone receptors could be involved in these important regulatory processes by ac…”
BackgroundPharmacotherapies for Treatment of Cocaine Abuse: Preclinical Aspects
Carroll, F. I., Howell, L. L., & Kuhar, M. J. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9706729 · Cited by 202
Michael, H., Härkönen, P. L., Väänänen, H. K., & Hentunen, T. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050803 · Cited by 200
“Previous studies, which have been performed with avian osteoclasts,((15)) rabbit osteoclasts,((57)) rat osteoclasts,((58)) murine marrow cells,((59)) human marrow cells,((60,61)) and human giant tumor cells of bone,((62)) have shown that E2 inhibited both osteoclast formation and resorption.”
BackgroundIntestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis
Xu, X., Jia, X., Mo, L., Liu, C., Zheng, L., Yuan, Q., & Zhou, X. (2017) · Bone Research · doi:10.1038/boneres.2017.46 · Cited by 199
A role for TGFβ1 in osteoclast differentiation and survival
Fuller, K., Lean, J. M., Bayley, K. E., Wani, M. R., & Chambers, T. J. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.13.2445 · Cited by 197
Ca2+ as an extracellular signal in bone
Dvorak, M. M., & Riccardi, D. (2003) · Cell Calcium · doi:10.1016/j.ceca.2003.10.014 · Cited by 198
Murakami, T., Yamamoto, M., Yamamoto, M., Ono, K., Nishikawa, M., Nagata, N., Motoyoshi, K., & Akatsu, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9723 · Cited by 195
The Interplay between the Bone and the Immune System
Mori, G., D’Amelio, P., Faccio, R., & Brunetti, G. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/720504 · Cited by 196
Heino, T. J., Hentunen, T. A., & Väänänen, H. K. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10109 · Cited by 191
Wang, W., Zhou, G., Hu, M. C. ‐., Yao, Z., & Tan, T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22771 · Cited by 188
Matrix Regulation of Skeletal Cell Apoptosis
Adams, C. S., Mansfield, K. D., Perlot, R. L., & Shapiro, I. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006492200 · Cited by 190
Khosla, S., Atkinson, E. J., Dunstan, C. R., & O’Fallon, W. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8397 · Cited by 191
Breast cancer bone metastases: pathogenesis and therapeutic targets
Brook, N., Brook, E., Dharmarajan, A., Dass, C. R., & Chan, A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.003 · Cited by 194
Time to Talk SENS: Critiquing the Immutability of Human Aging
de Grey, A. D. N. J., Ames, B. N., Andersen, J. K., Bartke, A., Campisi, J., Heward, C. B., McCarter, R., & Stock, G. B. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02115.x · Cited by 189
The osteoclast, bone remodelling and treatment of metabolic bone disease
Boyce, B. F., Rosenberg, E., de Papp, A. E., & Duong, L. T. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02717.x · Cited by 192
Self-citation
Metadata
- Authors
- Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., & Boyce, B. F.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- Boyce, Brendan F.
- Venue
- Nature Medicine
- Published
- 1996-10
- Volume
- 2
- Issue
- 10
- Pages
- 1132-1136
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2016674232
- Cited by
- 813
- References
- 27
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 13 · 2023: 20 · 2022: 23 · 2021: 24 · 2020: 23 · 2019: 22 · 2018: 22 · 2017: 15 · 2016: 22 · 2015: 27 · 2014: 16 · 2013: 29 · 2012: 27
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ar039529-07)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 45299)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR 43510, AR 39529, R01AR043510)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- estrogen, osteoclast apoptosis, TGF-beta, postmenopausal osteoporosis, estradiol, tamoxifen, bone resorption, estrogen deficiency, anti-TGF-beta antibody, estrogen replacement therapy, bone loss prevention
- MeSH terms
- Animals, Bone and Bones, Bone Resorption, Cell Count, Cells, Cultured, Estradiol, Estrogen Antagonists, Female, Gene Expression Regulation, Humans, Mice, Inbred C57BL, Organ Size, Osteoblasts, Osteoclasts, Ovariectomy, Tamoxifen, Uterus, Osteoporosis, Postmenopausal, Transforming Growth Factor beta, Apoptosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
